title: Through the eyes of women: the partners' perspective on tadalafil.
abstract: OBJECTIVE
  To evaluate patient and female partner responses on the efficacy of, and overall satisfaction with, tadalafil to treat erectile dysfunction using sexual encounter profile (SEP) diaries.
  
  
  METHODS
  Data were pooled from four double-blind, placebo-controlled, 12-week trials that included 746 couples. Patients were randomized to placebo or tadalafil 10 or 20 mg. Efficacy was evaluated by the mean per-patient/per-partner percentage of "yes" responses to patient SEP questions 1, 2, and 5 and partner SEP questions 1 to 3 (erection achievement, penetration, and overall satisfaction with the sexual experience, respectively) for tadalafil versus placebo. For each SEP question, the number of postbaseline intercourse attempts when each couple agreed on the outcome was tabulated and divided by the total number of postbaseline attempts to calculate the mean percentage of agreement by couple. The overall satisfaction with successful postbaseline intercourse attempts was determined.
  
  
  RESULTS
  Tadalafil significantly improved the responses for the patient and partner-evaluated SEP questions (P <0.001, both doses versus placebo). Partners tended to report greater overall satisfaction than patients at baseline and postbaseline. The mean percentage of agreement by couple was approximately 98% for erection achievement and penetration and 85% for overall satisfaction. For successful intercourse attempts, patients and partners treated with tadalafil reported more overall satisfaction than those treated with placebo (P <0.05, tadalafil versus placebo comparisons).
  
  
  CONCLUSIONS
  Partners reported significantly improved overall sexual satisfaction and corroborated the man's report of improved erections and penetration ability with tadalafil 10 mg or 20 mg. Men reported improved erection achievement, penetration, and overall satisfaction with the sexual experience after taking tadalafil.
authors.affiliation: Department of Urology, Case School of Medicine, Cleveland, Ohio, USA. sxa6@po.cwru.edu
authors.forename: Stanley E
authors.initials: SE
authors.lastname: Althof
authors.forename: J Francois
authors.initials: JF
authors.lastname: Eid
authors.forename: David R
authors.initials: DR
authors.lastname: Talley
authors.forename: Gerald B
authors.initials: GB
authors.lastname: Brock
authors.forename: Marian E
authors.initials: ME
authors.lastname: Dunn
authors.forename: Molly E
authors.initials: ME
authors.lastname: Tomlin
authors.forename: Fanni
authors.initials: F
authors.lastname: Natanegara
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Ahuja
mesh_terms: D000368:Aged; D002243:Carbolines / Q000627:therapeutic use*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D018454:Spouses; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil